RxDoctor Payments Data

Ralica Houston, PA

Physician Assistant · San Antonio, TXNPI 1699214577

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 45 payments — averaging $25.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$371
  • Pfizer$185
  • AbbVie$177
  • Novartis$131
  • Lilly USA, LLC$125
  • Novo Nordisk$116
  • plus $62 from 1 others

What the payments were for

  • Food & beverage$1,166100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott12$371
Pfizer12$185
AbbVie10$177
Novartis6$131
Lilly USA, LLC1$125
Novo Nordisk1$116
Amgen3$62

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,166 in reported general payments places this provider in the 65th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$25,894
Medicare patients
74
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$49,496
Repatha SureclickEvolocumab18$19,844
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,180
LinzessLinaclotide15$9,344
Tresiba Flextouch U-100Insulin Degludec11$7,105
Aripiprazole12$2,130
Bupropion XlBupropion Hcl15$1,563
Albuterol Sulfate HfaAlbuterol Sulfate48$1,552
Ventolin HfaAlbuterol Sulfate14$1,107
Levothyroxine Sodium96$1,000
Pregabalin15$775
Fluticasone Propionate40$760
Montelukast Sodium43$646
Atorvastatin Calcium81$625
Omeprazole48$592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$49,49629 claims
AbbVieLinzess$177$9,34415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →